ABCB 1 C 3435T POLYMORPHISM AND CLINICAL FEATURES OF PEPTIC ULCER PATIENTS TAKING PROTON PUMP INHIBITORS

Introduction. ABCB 1 gene localized on seventh chromosome encodes ABC-transporter P-glycoprotein. Proton pump inhibitors are known to be substrates of P-glycoprotein. Studies showed that C 3435T genetic polymorphism of ABCB 1 might influence proton pump inhibitors-based acid suppression and Helicobacter pylori eradication rates. From this point of view, studying the relation between C 3435T polymorphism of ABCB 1 and clinical and demographic features of peptic ulcer patients taking proton pump inhibitors may have clinical relevance. The aim of the study - to find the connection between C 3435T polymorphism of ABCB 1 and clinical and demographic features of patients with peptic ulcer taking omeprazole. Methods. Fifty peptic ulcer patients (19 men, 31 women), who were on treatment with omeprazole in Moscow clinics, aged 18-77 years (mean age 51.5±14.9 years) were enrolled. Six milliliters of venous blood were taken from patients in K2-EDTA tubes. C 3435T polymorphism of ABCB 1 gene was analyzed using real-time polymerase chain reaction (PCR). Results. CC genotype of ABCB 1 was found in 11 (22 %) patients, CT genotype - in 26 (52 %) patients, TT genotype - in 13 (26 %) patients. All genotypes were in Hardy-Weinberg equilibrium (p=0.77). There were no statistically significant differences in distribution of CC, CT, TT genotypes of ABCB 1 gene in patients depending on stomach or duodenum ulcer localization (6,8 %, 15,9 %, 9,1 % vs. 13,6 %, 34,1 %, 20,5 %, respectively), existence or absence of family history of peptic ulcer (14,3 %, 33,3 %, 9,6 % vs. 4,7 %, 23,8 %, 14,3 %, respectively), existence or absence of exacerbation after diagnosed peptic ulcer (14,8 %, 18,6 %, 3,7 % vs. 11,1 %, 37 %, 14,8 %, respectively), existence or absence of ulcer complications (15,1 %, 9,1 %, 9,1 % vs. 12,1 %, 45,5 %, 9,1 %, respectively), less than 1 cm or 1 cm and more ulcer according to gastroscopy (7,1 %, 28,6 %, 28,6 % vs. 7,1 %, 7,1 %, 21,5 %, respectively), less than 30 or 30 and more total score of GSRS scale (10 %, 30 %, 30 % vs. 5 %, 15 %, 10 %, respectively), Fisher’s Exact test, p>0.05. Conclusion. There is a high prevalence of C 3435T polymorphisms of ABCB 1 gene in peptic ulcer patients of Moscow region. There were no statistically significant differences between ABCB 1 genotype and clinical and demographic features of peptic ulcer patients.

ABCB 1, ABCB 1, P-glycoprotein, pharmacogenetics, proton pump inhibitor, omeprazole, peptic ulcer

1. Jażdżyk M, Sałagacka A, Zebrowska M, Balcerczak M, Mirowski M, Balcerczak E. ABCB 1 expression in peptic ulcer patients and its connection with H. pylori Infection. Ann Clin Lab Sci. 2014; 44(3): 294-7.

2. Higgins CF. Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci. 1992; 17: 18-21.

3. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. CancerRes. 1970; 30(4): 1174-84.

4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986; 47(3): 381-9.

5. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. BiochimBiophysActa. 1976; 455(1): 152-62.

6. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979; 39(6 Pt 1): 2200-3.

7. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR 1 (P-glycoprotein): recent advances and clinical relevance. ClinPharmacolTher. 2004; 75(1): 13-33.

8. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl AcadSci USA. 2000; 97: 3473-8.

9. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR 1, ABCB 1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005; 15(10): 693-704.

10. Furuta T, Sugimoto M, Shirai N, et al. Effect of MDR 1 C 3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C 19 genotypes and 23S rRNA genotypes of H.pylori. Aliment PharmacolTher. 2007; 26: 693-703.

11. Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M. Effect of CYP2C 19 and MDR 1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol. 2005; 61: 375-379.

12. Маев И. В., Кучерявый Ю. А., Андреев Д. Н. Причины неэффективности антигеликобактерной терапии. РЖГГК. 2013; 6: 62-72.

13. Komoto C, Nakamura T, Sakaeda T, et al. MDR 1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug MetabPharmacokinet. 2006; 21(2): 126-32.

14. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB 1 (MDR 1, multidrug resistance transporter) gene. Pharmacogenetics. 2003; 13(8): 481-94.

15. Omar M, Crowe A, Parsons R, Ee H, Tay CY, Hughes J. P-glycoprotein expression in Helicobacter pylori-positive patients: the influence of MDR 1 C 3435T polymorphism. JDigDis. 2012; 13: 414-420.

16. Babic Z, Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, Troskot R. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. WorldJGastroenterol. 2005; 11: 2720-2725.